The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women
© Evans and Beil; licensee BioMed Central Ltd. 2006
Received: 16 May 2006
Accepted: 31 July 2006
Published: 31 July 2006
Common genetic variants in the PCSK9 gene have been reported to be associated with both elevated and exceptionally low LDL levels. The association of a common haplotype, encompassing the E670G single nucleotide polymorphism, with LDL levels reported by Chen et al (J Am Coll Cardiol 2005; 45: 1644) was not confirmed by Kotowski et al (Am J Hum Genet 2006; 78:410–422).
The incidence of the E670G SNP was determined in 506 patients attending the lipid clinic, University Hospital, Hamburg.
The frequency in men with polygenic hypercholesterolemia, 0.11 was significantly higher than in men with LDL<50th percentile, 0.03, p = 0.01. In women there was no difference in the allele frequencies between the two groups.
In a European population the E670G SNP in the PCSK9 gene is associated with increased LDL in men but not in women.
Elevated plasma LDL is recognised as a major risk factor for the development of atherosclerosis and coronary vascular disease . Mutations in the LDLR and APOB genes are well established as monogenetic causes of familial hypercholesterolemia (FH) and familial defective apoB (FDB) respectively . These conditions are characterised by elevated LDL and increased risk of CVD. More recently mutations in the PSCK9 gene  have been identified as the cause of a third monogenetic form of famiial hypercholesterolemia (FH3). However monogenetic hypercholesterolemia represents only a small proportion of patients with elevated LDL, in most cases hypercholesterolemia is thought to be the result of a combination of dietary and genetic factors and is refered to as polygenic hypercholesterolemia.
Since mutation in the PCKS9 gene can lead to monogenic hypercholesterolemia, it is possible that common genetic variation in the gene may contribute to polygenic hypercholesterolemia. Through sequencing the PCSK9 gene of probands with LDL below the 5th and above the 95th percentile, Kotowski et al  described a spectrum of variants which contribute to plasma levels of LDL. They found variants which were associated with low LDL and others which were associated with elevated LDL. Chen et al  performed a haplotype analysis of the PCSK9 gene in subjects taking part in the LCAS study. They identified a haplotype, characterised by the G allele of the 23968A>G (E670G) SNP, which was associated with increased LDL levels and confirmed their observation in probands from the TexGen study representing a normal population (mean LDL 108 mg/dl). In contrast, Kotowski et al  found no association of this SNP with LDL levels in subjects taking part in the Dallas Heart Study, also a population based study from Texas. The association of the IVS1-161C>T and I475V SNPs with lower LDL reported in Japenese subjects by Shioji et al.  could not be confirmed by Kotowski et al .
In this study we determine the incidence of the 23968A>G (E670G) polymorphism in the PCSK9 gene in patients attending the lipid outpatients clinic of the University Hospital in Hamburg. Given the conflicting reports between American and Japenese populations, we consdered it worthwhile to ascertain the role, if any, of this SNP in polygenic hypercholesterolemia in a European population. We reasoned that if this variant does indeed cause an increase in LDL then it should show a higher frequency amongst patients with polygenic hypercholesterolemia.
Clinical characteristics of the patients
Total cholesterol (mg/dl)
Lipoprotein (a) (mg/dl)
Type 2 diabetes (n)
Coronary heart disease (n)
Plasma cholesterol (TC) and triglycerides (TG) were determined using the GPO-PAP and CHOD-PAP kits respectively from Boehringer Mannheim. HDL cholesterol was determined following precipitation of apo B containing lipoproteins with phosphotungstate (Boehringer Mannheim).
DNA was extracted using QIAamp DNA Blood mini kits from Qiagen following the manufacturer's protocol. For the determination of the frequency of the 23968A>G (E670G) polymorphism a 167 bp DNA fragment was obtained following PCR with the following primers: forward primer: TACGCCGTAGACAACACG; reverse primer: TCCCCAGACACCCATCCTGG. Digestion with mnlI results in fragments of 100 bp and 67 bp for the common A allele. Carriers of the variant G allele were confirmed by digestion with sau96I.
Allele frequencies were determined by gene counting and compared using Fisher's exact test. Continuous variables were compared using the Mann Whitney test. A p value of 0.05 or below was considered statistically significant. Analysis was performed using Statistica software.
The frequency of the G allele was 0.05 (AA 458, AG 45, GG 3) which lies between that observed in the TexGen population, 0.044 (AA 291, AG 28, GG 0) and that reported for the LCAS study, 0.074 (AA 324, AG 41, GG 7) by Chen et al in their original study. There was no statistical significant difference in the frequency of the G allele in patients with LDL below the 50th percentile for age and sex, 0.044 (AA 93, AG 9, GG 0), those with LDL between the 50th and 95th percentiles 0.064 (AA 160, AG 20, GG 1) and those with LDL above the 95th percentile, 0.064 (AA 205, AG 26, GG 2). Patients with LDL above the 95th percentile form a mixed group consisting of probands with monogenic hypercholesterolemia and those with polygenic hypercholesterolemia. Nearly all cases of FDB are the result of the APOB R3500Q mutation. Therefore the incidence of this mutation was determined in all the probands and eight patients were found to be carriers of the variant. Assuming that an LDL level above 300 mg/dl allows a diagnosis of familial hypercholesterolemia with 95% probability, 56 patients, 3 of whom were APOB3500 carriers fall into this group. The frequency of the G allele was 3/56 probands with LDL>300 mg/dl and 1/8 APOB 3500 heterozygotes. Removing these patients with probable monogenic hypercholesterolemia from the group of those with LDL above the 95th percentile results in an increase in the frequency of the G allele in the remaining probands with polygenic hypercholesterolemia to 0.076 (AA 148, AG 22, GG 2), which although higher than that seen in patients with LDL below the 50th percentile the difference is not statistically significant. Power to detect difference between polygenic hypercholesterolemia and LDL<50th percentile is 0.22.
Plasma lipid levels according to PCSK9 E670G genotype
A. All patients
Total cholesterol (mg/dl)
Lipoprotein (a) (mg/dl)
B. Monogenic Hypercholesterolemia excluded
Total cholesterol (mg/dl)
Lipoprotein (a) (mg/dl)
The G allele of the E670G SNP in the PCSK9 gene was present at an increased frequency in men, but not women, with polygenic hypercholesterolemia thus partly confirming the findings of Chen et al . The majority of the probands in the LCAS study were men (310 out of 372) and in the TexGen study, two thirds of the probands were male (210 from 319), they did not separately analyse the incidence of the SNP for men and women accounting for their failure to observe a sex difference in the role of the SNP. The Dallas Study provides no information on the influence of sex on the effect of the SNP on lipid levels . Whereas Chen et al  performed an extensive haplotype analysis we have only investigated the association with the E670G SNP which Chen et al  utilized as marker for the haplotype associated with LDL levels, if the haplotype structure were to be significantly different in our population this could account for differences in our findings. Since the mechanism by which variation in the PCSK9 gene affects LDL levels is unknown [4, 5] we have no explanation for the different effect of such variation between men and women. We did not observe a significant affect of the SNP on LDL levels. This is not unexpected since we were investigating a hyperlipidemic population and since elevated LDL can be the result of common genetic variants in a number of candidate genes we would probably not detect a modest effect in this population.
We present evidence that a common genetic variant in the PCSK9 gene contributes to polygenic hypercholesterolemia in men of European origin.
We thank Edda George for excellent technical assistance.
- Third report of the National Cholesterol EducationProgramme (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III): final report. Circulation. 2002, 106: 3143-421.
- Rader DJ, Cohen J, Hobbs HH: Monogenichypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003, 111: 1795-1803. 10.1172/JCI200318925.View ArticlePubMedPubMed CentralGoogle Scholar
- Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devilliars M, Cruard C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanau B, Lecerf J, Luc G, Moulin P, Wiessenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C: Mutations in PCSK9 cause autosomal dominanthypercholesterolemia. Nat Genet. 2003, 34: 154-156. 10.1038/ng1161.View ArticlePubMedGoogle Scholar
- Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen JC, Hobbs HH: A spectrum of PCSK9 alleles contributes to plasma levels of low density lipoprotein cholesterol. Am J Hum Genet. 2006, 78: 410-22. 10.1086/500615.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen SN, Ballantyne CM, Gotto AM, Tan Y, Willerson JT, Marian AJ: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and the severity of coronary atherosclerosis. J Am Coll Cardiol. 2005, 45: 1611-1619. 10.1016/j.jacc.2005.01.051.View ArticlePubMedPubMed CentralGoogle Scholar
- Shioji K, Mannami T, Kokubo Y, Inamoto N, Takagi S, Goto Y, Nonogi H, Iwai N: Genetic variants in PCSK9 affect the cholesterol level in Japenese. J Hum Genet. 2004, 49: 109-114. 10.1007/s10038-003-0114-3.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/7/66/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.